# Effect of Delivery Route on PK of Sufentanil NanoTab

> **NCT01639729** · PHASE1 · COMPLETED · sponsor: **Talphera, Inc** · enrollment: 25 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Treatment A: Sufentanil IV
- **DRUG:** Treatment B: Sufentanil NanoTab Sublingual
- **DRUG:** Treatment C: Sufentanil NanoTab Buccal
- **DRUG:** Treatment D: Sufentanil NanoTab Oral

## Key facts

- **NCT ID:** NCT01639729
- **Lead sponsor:** Talphera, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01639729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01639729, "Effect of Delivery Route on PK of Sufentanil NanoTab". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01639729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*